

Table S2. Treatment Pattern of Patients With mCRPC From mCRPC Diagnosis to Third-Line Treatment for the Population of Patients With Metastasis Before mCRPC Diagnosis –

Aggregated Data (n = 122)

Before mCRPC, n (%)		First line, n (%)		Second line, n (%)		Third line, n (%)					
ADT only	62 (50.8)	ABI or ENZA	23 (37.1)	ABI or ENZA	2 (8.7)	LOSS	2 (100.0)				
				DOC	9 (39.1)	ABI or ENZA	3 (33.3)				
						CAB	2 (22.2)				
						LOSS	4 (44.4)				
				LOSS	12 (52.2)	LOSS	12 (100.0)				
				AA	16 (25.8)	ABI or ENZA	7 (43.8)	ABI or ENZA	1 (14.3)		
								DOC	1 (14.3)		
								LOSS	5 (71.4)		
								DOC	2 (12.5)	ABI or ENZA	1 (50.0)
										LOSS	1 (50.0)
								LOSS	5 (31.3)	LOSS	5 (100.0)
				DOC	23 (37.1)	ABI or ENZA	8 (34.8)	ABI or ENZA	3 (37.5)		
CAB	1 (12.5)										
DOC	1 (12.5)										
Others	2 (12.5)	ABI or ENZA	1 (50.0)								
		DOC	1 (50.)								

						LOSS	3 (37.5)
				AA	1 (4.3)	LOSS	1 (100.0)
				CAB	3 (13.0)	ABI or ENZA	2 (66.7)
						LOSS	1 (33.3)
				LOSS	11 (48.7)	LOSS	11 (100.0)
ADT + ABI	8 (6.6)	ABI or ENZA	3 (37.5)	ABI or ENZA	1 (33.3)	LOSS	1 (100.0)
				DOC	2 (66.7)	LOSS	2 (100.0)
		DOC	5 (62.5)	ABI or ENZA	1 (20.0)	CAB	1 (100.0)
				CAB	2 (40.0)	LOSS	2 (100.0)
				LOSS	2 (40.0)	LOSS	2 (100.0)
ADT + AA	35 (28.7)	ABI or ENZA	15 (42.9)	ABI or ENZA	2 (13.3)	LOSS	2 (100.0)
				DOC	11 (73.3)	CAB	3 (27.3)
						LOSS	8 (72.7)
				LOSS	2 (13.3)	LOSS	2 (100.0)
		AA	2 (5.7)	ABI or ENZA	1 (50.0)	DOC	1 (100.0)
				DOC	1 (50.0)	LOSS	1 (100.0)
		DOC	18 (51.4)	ABI or ENZA	11 (61.1)	ABI or ENZA	1 (9.1)
						CAB	3 (27.3)
						DOC	2 (18.2)
						LOSS	5 (45.5)

				CAB	3 (16.7)	ABI or ENZA	1 (33.3)
						LOSS	2 (66.7)
				LOSS	4 (22.)	LOSS	4 (100.0)
ADT + DOC	17 (13.9)	ABI or ENZA	12 (70.6)	ABI or ENZA	4 (33.3)	CAB	2 (50.0)
						LOSS	2 (50.0)
				DOC	5 (41.7)	CAB	1 (20.0)
						LOSS	3 (20.0)
						Others	1 (20.0)
				LOSS	3 (25.0)	LOSS	3 (100.0)
		AA	1 (5.9)	LOSS	1 (100.0)	LOSS	1 (100.0)
		CAB	3 (16.6)	LOSS	3 (100.0)	LOSS	3 (100.0)
		DOC	1 (5.9)	LOSS	1 (100.0)	LOSS	1 (100.0)

AA: first-generation anti-androgen (bicalutamide or flutamide); ABI: abiraterone; ADT: androgen deprivation therapy; CAB: cabazitaxel; DOC: docetaxel; ENZA: enzalutamide; LOSS: information lost in tracking; mCRPC: metastatic castration-resistant prostate cancer.